Investors should remain long and get ready to buy on pullbacks, funds manager Sarat Sethi says.» Read More
CNBC's David Faber reports the latest details on Illumina's recommendation to shareholders to reject Roche's takeover offer.
Larry Kudlow reports the latest details on a North Korean rocket launch, and CNBC's Seema Mody reports Google beat on earnings and announces a 2-for-1 stock split.
Take a look at some of Monday’s morning movers:
Take a look at some of Wednesday’s morning movers:
Find out what’s going up, what’s going down and whether our traders would double down, fade or run in the other direction!
Take a look at some of Thursday’s morning movers:
Take a look at some of Monday morning’s early movers:
Jay Flatley, Illumina CEO, discusses fending off Roche's unsolicited bid as well as the future of his company.
CNBC's David Faber has details on the chairman of Leap Wireless filing for an offering for shares of the company. Also, an update on Illumina.
Take a look at some of Monday morning's early movers:
Considering Illumina just adopted a poison pill defense strategy, you might think a deal with Roche is out of the question. But Karen Finerman says it's not.
Karen Finerman, Metropolitan Capital Advisors, and Fast Money trader, provides insight on what's next for Illumina, on the heels its recent rejection of Roche's offer.
Roche is willing to spend $5.7 billion on what could be a hostile takeover of Illumina to get into the gene-sequencing market, CEO Severin Schwan told CNBC Friday.
Insight on the value that will be created by a transaction with Illumina, with Severin Schwan, Roche CEO, who discusses Roche's offer for Illumina.
Following are moves you might have missed. Find out why shares of D.R. Horton and Honeywell popped while Illumina and Altria dropped.
CNBC's Kayla Tausche has the details on the Roche tender offer that may be filed today.
Amgen and Celgene, looking to boost oncology offerings, announced separate deals for small biotech companies Thursday, the latest in what analysts expect to be a major wave of biotech mergers.
Stocks ended near session highs Wednesday, reversing their early declines, as the market cheered news that the Fed will not raise interest rates until at least 2014 in addition to maintaining its highly accommodative stance to support the recovery.
Cramer ticks off the many winning trades today.
Illumina landed squarely on Karen Finerman’s trader radar Wednesday with the company in the cross hairs of a hostile bid from Roche.